Genfit Rises Most Since 2006 on Drug Trial Results: Paris Mover

Genfit (ALGFT), a French drug developer, rose the most since 2006 in Paris trading after saying an experimental drug met all the goals of a mid-stage clinical trial in treating risk factors associated with diabetes.

Genfit rose 84 percent to 3.45 euros, giving the company a market value of 47 million euros ($62 million). It was the biggest advance ever for the company, which first sold shares to the public in December 2006.

The drug, GFT505, improved the liver’s sensitivity to insulin, and helps with a condition called dyslipidemia, which includes low levels of so-called good cholesterol and elevated readings of triglycerides, or fats in the bloodstream, the Loos, France-based company said in a statement. There were no adverse side effects, the company said.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.